Mistletoe Extracts–Health Professional Version (PDQ®)

SECTIONS

Changes to This Summary (04/01/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Human/Clinical Studies

Added Mansky et al. as reference 41.

Added text about a small uncontrolled trial of mistletoe plant extract from the same manufacturer of abnobaVISCUM in patients with nonmuscle invasive bladder cancer that showed the safety of intravesical administration and had response rates of 56%, which was consistent with the published results of other treatments for bladder cancer (cited Rose et al. as reference 44).

This summary is written and maintained by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section

Summary of the Evidence for Mistletoe Extracts

Next section >

About This PDQ Summary